131I-mIBG therapy in relapsed/refractory neuroblastoma: an old bridge to the future
Maria Antonietta De Ioris, Maria Felicia Villani, Francesca Del Bufalo, Claudio Altini et autres
BACKGROUND: I-mIBG) treatment as a tool to reduce tumour burden before novel immunotherapies is not defined. PATIENTS AND METHODS: ), supported by autologous haematopoietic stem cell rescue. The activity of the first administration was 444 MBq (12 mCi/kg), while the second dose …
it (code pays fourni par la source)